BeiGene employees acquire shares through ESPP

BeiGene Medicines Ltd. announced an update on share purchases made under its 2018 Employee Share Purchase Plan (ESPP). As of August 29, 2025, a total of 62,962 American Depositary Shares (ADSs) were purchased by 3,932 eligible employees. These purchased ADSs represent 818,506 underlying shares, constituting approximately 0.05% of the total issued shares. The offering period for these purchases ran for six months, from March 3, 2025, to August 29, 2025.

The purchase price for the ADSs was $208.7005 per ADS, representing an 85% discount off the lower of the Nasdaq closing prices on the first and last business days of the offering period. The total payroll deduction amounts authorized by eligible employees during this period amounted to $13,449,524.79. The company stated that no clawback mechanism applies to the issuance of these shares, although they are subject to tax withholding. Participants are employees of the company or a designated subsidiary and do not include directors, chief executives, substantial shareholders, or individuals exceeding specific ownership limits.

The company's compensation committee determined that the grants, which lack performance targets and clawback mechanisms, are market-competitive and align with BeiGene's customary practice and the ESPP's purpose. Following these grants, 3,179,780 shares remain available for future grants under the 2018 ESPP. BeiGene believes the plan is in the best interests of the company and its shareholders, fostering employee retention and aligning employee interests with those of shareholders.